Teresa Sue Weber has sold BTMD and made no open-market buys since Jan 2023

Teresa Sue Weber (often referenced as Teresa “Terry” S. Weber) is a health care executive and corporate insider who has served as Chief Executive Officer and Director of biote Corp. (NASDAQ: BTMD), a hormone optimization and preventive health care company, and has reported insider trades in Biote’s securities.( She has led BioTE Medical LLC, Biote’s main operating company, as Chief Executive Officer since 2018 and was CEO & Director of biote Corp. from 2022 until her retirement from the CEO role in early 2025, after which she transitioned to a strategic advisor position to the company’s board.( Weber has been involved in Biote’s SPAC transaction with Haymaker Acquisition Corp. III and has been named in related investor litigation concerning that deal.(

Weber’s broader career includes senior leadership roles across health services and corporate transformation, notably serving as Chief Executive Officer of Amen Clinics, Inc. from 2015 to 2019 and as a partner at Mattioli Weber Consulting since 2013.( She has run companies with revenues ranging from $100 million to $2.5 billion and has focused on expanding access to bioidentical hormone replacement therapy and integrative wellness therapies through Biote’s nationwide provider network.( Weber holds an undergraduate degree from New College of Florida and a graduate degree from Purdue University, providing an academic foundation for her work in health care management and preventive medicine.(

Written by Perplexity from public sources.